Cargando…
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
BACKGROUND: Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in fem...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528179/ https://www.ncbi.nlm.nih.gov/pubmed/34059488 http://dx.doi.org/10.1016/j.clml.2021.04.013 |
_version_ | 1784586205503946752 |
---|---|
author | Bird, Sarah Cairns, David Menzies, Tom Boyd, Kevin Davies, Faith Cook, Gordon Drayson, Mark Gregory, Walter Jenner, Matthew Jones, John Kaiser, Martin Owen, Roger Jackson, Graham Morgan, Gareth Pawlyn, Charlotte |
author_facet | Bird, Sarah Cairns, David Menzies, Tom Boyd, Kevin Davies, Faith Cook, Gordon Drayson, Mark Gregory, Walter Jenner, Matthew Jones, John Kaiser, Martin Owen, Roger Jackson, Graham Morgan, Gareth Pawlyn, Charlotte |
author_sort | Bird, Sarah |
collection | PubMed |
description | BACKGROUND: Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored. PATIENTS AND METHODS: We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated. RESULTS: Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were more likely to meet the cytogenetic classification of high-risk (HiR) or ultra-high-risk disease (UHiR). There was no difference in progression-free survival (PFS) or overall survival (OS) between the sexes in the overall population. CONCLUSION: Our data suggest that the genetic lesions involved in the initiation and progression of MM may be different between the sexes. Although females were more likely to have the poor prognosis lesions t(14;16) and del(17p), and were more likely to be assessed as having HiR or UHiR disease, this was not associated with reduced PFS or OS. In female patients the trial treatment may have been able to overcome some of the adverse effects of high-risk cytogenetic lesions. MicroAbstract Multiple myeloma (MM) is more common in males compared to females but the reasons behind this are not well understood and the impact of sex on patient outcomes is unclear. This study demonstrates fundamental differences in genetic lesions underlying the biology of MM between males and females. However, we found that progression-free survival and overall survival were the same in both sexes. |
format | Online Article Text |
id | pubmed-8528179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85281792021-10-27 Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial Bird, Sarah Cairns, David Menzies, Tom Boyd, Kevin Davies, Faith Cook, Gordon Drayson, Mark Gregory, Walter Jenner, Matthew Jones, John Kaiser, Martin Owen, Roger Jackson, Graham Morgan, Gareth Pawlyn, Charlotte Clin Lymphoma Myeloma Leuk Original Article BACKGROUND: Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored. PATIENTS AND METHODS: We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated. RESULTS: Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were more likely to meet the cytogenetic classification of high-risk (HiR) or ultra-high-risk disease (UHiR). There was no difference in progression-free survival (PFS) or overall survival (OS) between the sexes in the overall population. CONCLUSION: Our data suggest that the genetic lesions involved in the initiation and progression of MM may be different between the sexes. Although females were more likely to have the poor prognosis lesions t(14;16) and del(17p), and were more likely to be assessed as having HiR or UHiR disease, this was not associated with reduced PFS or OS. In female patients the trial treatment may have been able to overcome some of the adverse effects of high-risk cytogenetic lesions. MicroAbstract Multiple myeloma (MM) is more common in males compared to females but the reasons behind this are not well understood and the impact of sex on patient outcomes is unclear. This study demonstrates fundamental differences in genetic lesions underlying the biology of MM between males and females. However, we found that progression-free survival and overall survival were the same in both sexes. Elsevier 2021-10 /pmc/articles/PMC8528179/ /pubmed/34059488 http://dx.doi.org/10.1016/j.clml.2021.04.013 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Bird, Sarah Cairns, David Menzies, Tom Boyd, Kevin Davies, Faith Cook, Gordon Drayson, Mark Gregory, Walter Jenner, Matthew Jones, John Kaiser, Martin Owen, Roger Jackson, Graham Morgan, Gareth Pawlyn, Charlotte Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title | Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title_full | Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title_fullStr | Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title_full_unstemmed | Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title_short | Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial |
title_sort | sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma xi trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528179/ https://www.ncbi.nlm.nih.gov/pubmed/34059488 http://dx.doi.org/10.1016/j.clml.2021.04.013 |
work_keys_str_mv | AT birdsarah sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT cairnsdavid sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT menziestom sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT boydkevin sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT daviesfaith sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT cookgordon sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT draysonmark sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT gregorywalter sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT jennermatthew sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT jonesjohn sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT kaisermartin sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT owenroger sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT jacksongraham sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT morgangareth sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial AT pawlyncharlotte sexdifferencesinmultiplemyelomabiologybutnotclinicaloutcomesresultsfrom3894patientsinthemyelomaxitrial |